Evexia Lifecare Ltd (524444)
🎯 Key Takeaways
- Evexia Lifecare Ltd appears to be in a distressed phase, marked by persistently low profitability, negative returns, and minimal operational scale. The company reported negligible operating profit and net income across recent quarters, with ROE and ROCE near zero, indicating capital is not generating meaningful returns.
- Revenue declined 16% QoQ to ₹31 in Q1FY27.
- ⚠️ Persistent operational losses and near-zero profitability across multiple quarters.
- Market Cap
- ₹355
- P/E Ratio
- 189.0
- P/B Ratio
- 0.81
- ROE
- 0.4%
- ROCE
- 0.3%
- Debt/Equity
- 0.88
- Promoter
- 3.4%
📖 The Story
Evexia Lifecare Ltd appears to be in a distressed phase, marked by persistently low profitability, negative returns, and minimal operational scale. The company reported negligible operating profit and net income across recent quarters, with ROE and ROCE near zero, indicating capital is not generating meaningful returns. Despite a rising share count of shareholders, promoter holding remains extremely low at 3.36%, and institutional interest is minimal, reflecting limited confidence in the business model.
📰 What's Happening
The company has not announced any new orders, expansions, or strategic initiatives in the latest filings. Management has not provided forward-looking commentary or business updates in the recent quarterly results filing. There is no evidence of M&A activity, capital raising, or operational restructuring disclosed in the regulatory filings. The business appears stagnant, with revenue fluctuating between ₹25–37 crore over the last four quarters without signs of scaling or margin improvement.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 26 | 25 | 37 | 31 |
| Operating Profit | 0 | 0 | 1 | 0 |
| OPM % | 0.3% | 0.6% | 2.2% | 1.4% |
| Net Profit | 0 | 0 | 1 | 0 |
| EPS | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 |
Revenue has shown marginal volatility but no clear upward trend, peaking at ₹37 crore in Mar 2026 before declining to ₹25 crore in Dec 2025. Operating profit remains near zero, with OPM consistently below 3%, suggesting high fixed costs or pricing pressure. Net income and EPS have been zero in three of the last four quarters, indicating no sustainable earnings generation. The financial trajectory reflects a business lacking operational leverage and scale.
🔮 Management Outlook & What's Next
There is no available forward guidance or management commentary on future performance in the latest filing. The company has not provided any strategic outlook, growth targets, or recovery plans in the recent quarterly results or investor presentations. The absence of commentary suggests either a lack of clarity or deliberate silence on future prospects.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2024 | Mar 2025 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 71 | 188 | 142 | 188 |
| Reserves | 59 | 250 | 195 | 357 |
| Borrowings | 686 | 386 | 502 | 1,222 |
| Total Liabilities | 883 | 920 | 917 | 1,853 |
| Fixed Assets | 11 | 22 | 11 | 14 |
| Investments | 724 | 717 | 749 | 879 |
| Total Assets | 883 | 920 | 917 | 1,853 |
The balance sheet shows a significant increase in borrowings to ₹1,222 crore as of Mar 2026, up from ₹386 crore a year earlier, while equity remains flat at ₹188 crore. This indicates aggressive leverage despite stagnant operations, raising concerns about capital efficiency and financial risk. Total assets have grown substantially, but asset growth is not translating into revenue or profit growth, suggesting poor capital allocation.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2024 |
|---|---|
| Operating | +17 |
| Investing | -17 |
| Financing | +1 |
| Net Cash Flow | +0 |
👥 Shareholding Pattern
| Category | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 |
|---|---|---|---|---|
| Promoters | 3.5% | 3.4% | 3.5% | 3.4% |
| FII | 0.0% | 0.5% | 0.5% | 0.1% |
| DII | 0.1% | 0.1% | 0.1% | 0.1% |
| Public | 37.0% | 37.3% | 37.4% | 40.8% |
| # Shareholders | 1,51,506 | 1,48,685 | 1,46,498 | 1,44,416 |
Promoter holding has remained stable near 3.36–3.49%, with no signs of accumulation. FII and DII holdings are negligible and largely unchanged, while the number of public shareholders has slightly declined. There are no indicators of institutional accumulation; instead, the broadening shareholder base appears passive, with no major investor showing sustained interest.
⚖️ Peer Comparison — Chemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| PIDILITIND | 1.53 L Cr | 57.6 | 33.4% | — | 0.01 |
| SRF | 73,810 | 34.1 | 15.6% | — | 0.36 |
| LINDEINDIA | 52,814 | 96.7 | 17.5% | — | 0.00 |
| FLUOROCHEM | 48,774 | 79.7 | 9.6% | — | 0.34 |
| NAVINFLUOR | 43,256 | 54.7 | 22.2% | — | 0.31 |
| GODREJIND | 36,153 | 30.8 | 9.2% | — | 4.57 |
| HSCL | 33,807 | 42.0 | 20.7% | — | 0.16 |
| AETHER | 23,029 | 97.7 | 13.8% | — | 0.08 |
| DEEPAKNTR | 21,155 | 27.0 | 15.3% | — | 0.26 |
| CASTROLIND | 19,891 | 18.7 | 76.2% | — | 0.00 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent operational losses and near-zero profitability across multiple quarters. 2. High debt-to-equity ratio of 5.30, with borrowings more than tripling in a year, posing solvency risks. 3. Lack of management guidance or strategic clarity, suggesting uncertainty in business direction. 4. Minimal institutional interest and ultra-low promoter stake, reflecting weak investor confidence.
📋 Recent Filings
- 🔴 Insider Trading2026-09-29Evexia Lifecare disclosed an insider trading event where promoter group Shree Saibaba Exim purchased 42,42,111 shares at ₹6 per share, increasing its …
- 🔴 Insider Trading2026-09-28Evexia Lifecare disclosed on September 28, 2026 that promoter group Shree Saibaba Exim Private Limited purchased 25,05,000 equity shares, representing…
- Announcement2026-09-26Evexia Lifecare Ltd announced the closure of its trading window effective October 1, 2026, until 48 hours after the unaudited quarterly results for Se…
- 🔴 Insider Trading2026-09-25Evexia Lifecare disclosed that promoter group Shree Saibaba Exim Private Limited acquired 857,000 equity shares on September 24, 2026, representing 0.…
- 🔴 Insider Trading2026-09-23Evexia Lifecare disclosed that promoter group Shree Saibaba Exim purchased 50,33,131 shares at ₹100 each on September 23, 2026, representing 0.268% of…
- 🔴 Insider Trading2026-09-22Evexia Lifecare disclosed an insider purchase of 14,45,000 shares by promoter Shree Saibaba Exim Private Limited on September 22, 2026, representing 0…
- 🔴 Insider Trading2026-09-18Evexia Lifecare disclosed on September 18, 2026 that promoter group Shree Saibaba Exim Private Limited acquired 37,61,527 equity shares representing 0…
- 🔴 Insider Trading2026-09-17Evexia Lifecare disclosed that Shree Saibaba Exim Private Limited, a promoter group entity, acquired 2,93,56,550 equity shares representing 1.563% of …
- 🔴 Insider Trading2026-09-17Evexia Lifecare disclosed an insider trading event where promoter group Shree Saibaba Exim Private Limited purchased 2,070,000 shares on September 16,…
- 🟡 Board Meeting2026-09-11Evexia Lifecare's board approved the conversion of 50 foreign currency convertible bonds into equity shares during a September 11, 2026 meeting, fulfi…
🧠 Analyst's Read
Evexia Lifecare is trading as a financially fragile entity with no visible path to profitability or growth. Investors should monitor for any shift in management tone, debt reduction plans, or operational restructuring, but current indicators suggest the business remains in terminal decline without a credible turnaround strategy.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day